{"id":"W2890697824","doi":"10.1200/jco.2016.34.15_suppl.3564","title":"Phase 1b extension study of cancer stemness inhibitor BB608 (napabucasin) administered in combination with FOLFIRI +/- bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bioactive Compounds and Antitumor Agents","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; FOLFIRI; Bevacizumab; Internal medicine; Colorectal cancer; Gastroenterology; Adverse effect; Irinotecan; Cancer; Oncology; Surgery; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001110146,0.001359913,0.00166794,0.0004296309,0.0003332909,0.000638379,0.0006103305,0.001057048,0.003393239],"category_scores_gemma":[0.0005862541,0.0006251217,0.0009062267,0.0003658192,0.000622687,0.0005472077,0.0003524813,0.002340093,0.0008263927],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008260593,"about_ca_system_score_gemma":0.001412164,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001540054,"about_ca_topic_score_gemma":0.003143323,"domain_scores_codex":[0.9996185,0.0001764841,0.00001729769,0.00006462003,0.00003344549,0.00008963341],"domain_scores_gemma":[0.9994981,0.00005945523,0.00009807148,0.00003947897,0.00003050352,0.0002744194],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6992967,0.09998213,0.00897419,0.0006311039,0.000948248,0.0003776149,0.0002969067,0.002110136,0.1151136,0.0001443461,0.002130882,0.06999417],"study_design_scores_gemma":[0.2807079,0.693943,0.01455295,0.00002391982,0.0003618707,0.000330033,0.00004352426,0.000749256,0.007303927,0.00006589471,0.001898419,0.00001925345],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953623,0.001074526,0.0003528123,0.0001879048,0.00005069791,0.001518928,0.0005536842,0.00005450068,0.000844562],"genre_scores_gemma":[0.9924982,0.0009486686,0.001173954,0.0003581626,0.00009002227,0.001387889,0.001676978,0.00002204375,0.001844049],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003393239,"threshold_uncertainty_score":0.01135147,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.206843173479304,"score_gpt":0.5463825819132724,"score_spread":0.3395394084339684,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}